Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Depreciation and Depletion (2025)

VYNE Therapeutics' Depreciation and Depletion history spans 1 years, with the latest figure at $6000.0 for Q2 2025.

  • For Q2 2025, Depreciation and Depletion changed N/A year-over-year to $6000.0; the TTM value through Jun 2025 reached $12000.0, changed N/A, while the annual FY2025 figure was $23000.0, 475.0% up from the prior year.
  • Depreciation and Depletion reached $6000.0 in Q2 2025 per VYNE's latest filing, roughly flat from $6000.0 in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $6000.0 in Q1 2025 to a low of $6000.0 in Q1 2025.